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Obesity is currently a serious worldwide public health problem, reaching pandemic levels.
For decades, dietary and behavioral approaches have failed to prevent this disease
from expanding, and health authorities are challenged by the elevated prevalence of
co-morbid conditions. Understanding how obesity-associated diseases develop from
a basic science approach is recognized as an urgent task to face this growing problem.
White adipose tissue (WAT) is an active endocrine organ, with a crucial influence on
whole-body homeostasis. WAT dysfunction plays a key role linking obesity with its
associated diseases such as type 2 diabetes mellitus, cardiovascular disease, and some
cancers. Among the regulators of WAT physiology, the calcium-sensing receptor (CaSR)
has arisen as a potential mediator of WAT dysfunction. Expression of the receptor
has been described in human preadipocytes, adipocytes, and the human adipose cell
lines LS14 and SW872. The evidence suggests that CaSR activation in the visceral
(i.e., unhealthy) WAT is associated with an increased proliferation of adipose progenitor
cells and elevated adipocyte differentiation. In addition, exposure of adipose cells to
CaSR activators in vitro elevates proinflammatory cytokine expression and secretion.
An increased proinflammatory environment in WAT plays a key role in the development
of WAT dysfunction that leads to peripheral organ fat deposition and insulin resistance,
among other consequences. We propose that CaSR may be one relevant therapeutic
target in the struggle to confront the health consequences of the current worldwide
obesity pandemic.
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INTRODUCTION
Obesity has turned into a pandemic disease, with a worldwide prevalence that has more than
doubled in the last three decades, even after multiple attempts to stop its expansion1. In 2014, more
than 1.900 billion adults were overweight, a number that comprises more than 600 million obese
individuals1. Besides being associated with disorders such as type 2 diabetes mellitus, hypertension,
1http://www.who.int/mediacentre/factsheets/fs311/en/.
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cardiovascular disease, and cancer (Guh et al., 2009), obesity
in itself is a death risk factor (Flegal et al., 2013). There is no
doubt that obesity reduces the quality of life and affects the world
economic development and productivity (Williams et al., 2005;
Slagter et al., 2015).
For decades, many investigations have focused on identifying
primary causes, preventive measures, and treatments for halting
obesity. Despite these efforts, the long-term impact has been
very small (Hafekost et al., 2013), and clinical trials testing
different lifestyle-oriented approaches have consistently yielded
disappointing results (Langeveld and DeVries, 2015; Ross et al.,
2015; Mason et al., 2016). Moreover, the epidemiology reveals
that governmental public health interventions focused on diet
and physical activity have not been able to decrease the
prevalence of obesity or even slow down its increase (Popkin
et al., 2012; Cabrera Escobar et al., 2013; Hawkes et al., 2015).
Pharmacological approaches have also failed to provide safe and
efficacious therapies with long-term relevant results (Yanovski
and Yanovski, 2014; Balaji et al., 2016). Considering this scenario,
it is clear that there is an urgent need for a deeper understanding
of the development of the obesity-associated diseases, and the
study of adipose tissue plays a pivotal role in this sense. As written
by Elmquist and Scherer (2012), “The solution for the obesity
epidemic might lie in better understanding adipocyte biology.”
It is now known that white adipose tissue (WAT) dysfunction is
key in the pathophysiology of obesity-related diseases, and the
study of novel regulators of this process is crucial to uncover
new therapeutic targets. In this context, our group showed the
presence of the Calcium-sensing receptor (CaSR) in human
preadipocytes and adipocytes (Cifuentes et al., 2005), and studies
in the last decade suggest that its activation is involved in WAT
dysfunction (Villarroel et al., 2014). The present review describes
the evidence and perspectives of the role of CaSR in WAT
and obesity, as a new player in this complex and multifactorial
disorder.
WHITE ADIPOSE TISSUE: A KEY
HOMEOSTATIC ORGAN
WAT is currently regarded as a dynamic organ with an
extraordinary capacity to expand or decrease, according to
the energy status of the organism (Pellegrinelli et al., 2016).
There is considerable interest in studying WAT due to
its relevance as an endocrine organ and as a whole-body
metabolic regulator, particularly in light of the current obesity
epidemic. The main functional component of WAT is the
adipocyte, which specializes in storing energy as triglycerides
and releasing it as fatty acids. The tissue is also composed of
the so-called stroma-vascular fraction, which contains adipocyte
progenitor cells (preadipocytes), and fibroblasts, as well as
endothelial, smoothmuscle, and immune cells. Besides its storage
function, WAT also regulates whole-body energy homeostasis
through the production of regulatory paracrine/endocrine
molecules, termed adipokines (Rosen and Spiegelman, 2014).
These secretory products control a wide variety of biological
functions (Figure 1A), such as appetite, energy expenditure,
body temperature, glucose homeostasis, insulin sensitivity,
inflammation, blood clotting, reproduction, and ageing (Berry
et al., 2013; Hyvönen and Spalding, 2014).
It is well-accepted that body fat distribution largely determines
whether metabolic and cardiovascular comorbidities develop
in an obese individual, favoring their occurrence when
fat accumulation occurs at the abdominal level (“central
obesity”; Jensen, 2008). The subcutaneous and the visceral
compartments (Figure 1B) have very different clinical
implications. Proliferation of the subcutaneous adipose tissue
is considered positive, as it leads to increased “healthy” storage
capacity (Gustafson et al., 2015). Inflammatory cues associated
with obesity lead to impaired expansibility of the subcutaneous
depots (Tchernof and Després, 2013). As a consequence,
enlargement of visceral preadipocytes drives more inflammation
and the increase of ectopic fat depots (Smith, 2015), associated
with pathologic effects (Gustafson et al., 2009; Ye and Gimble,
2011). Ectopic fat accumulation leads to lipotoxicity where fatty
acids are accumulated in peripheral tissues, impairing cellular
signaling, and functions (Lee et al., 2013), constituting what has
been termed “adiposopathy”(Bays, 2014).
Adiposopathy takes place when obesity-triggered changes,
such as adipocyte hypertrophy and lipid overload, prevent
WAT from properly performing its storage and endocrine
functions (Gustafson et al., 2009). Dysfunctional adipocytes
develop an overall inflammatory state, secreting cytokines
that result in the infiltration of macrophages, which in turn
produce higher amounts of proinflammatory cytokines. Such
environment further compromises normal adipocyte function,
particularly triglyceride deposition (Guilherme et al., 2008).
This results in increased circulating free fatty acids and ectopic
fat accumulation, ultimately leading to insulin resistance, and
functional impairment in other organs, especially skeletal muscle.
CaSR: A ROLE IN ADIPOSE TISSUE
DYSFUNCTION
CaSR is an extracellular Ca2+ sensor, originally described in
the parathyroid gland as a regulator of parathyroid hormone
secretion and circulating Ca2+ levels (Brown et al., 1993;
Garrett et al., 1995). CaSR is a G-protein coupled receptor
with 7 transmembrane helices and a very complex signaling
network (Figure 1C) comprising orthosteric and allosteric
modulators (Cavanaugh et al., 2012). Among the many non-
Ca2+-homeostatic roles that have been described for the CaSR,
its involvement in WAT physiology emerged since its presence
in human WAT was reported in 2005 (Cifuentes et al., 2005).
CaSR activation in WAT is associated, by different mechanisms,
with alterations consistent with a dysfunctional phenotype
(Figure 2A). Activation of CaSR in human adipose cells, as well
as WAT explants, elevates the expression of the proinflammatory
cytokines interleukin 6 (IL6), chemokine C-C motif ligand
2 (CCL2), interleukin 1β (IL1β), and tumor necrosis factor
alpha (TNFα; Cifuentes et al., 2012), which have been linked
with adipose dysfunction and the cardiovascular and metabolic
consequences of obesity. In addition, CaSR activation stimulates
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FIGURE 1 | White adipose tissue (WAT) and the Calcium-sensing receptor (CaSR). (A) Functions of the WAT. Adipocytes store lipids in the form of triglycerides
and release them as fatty acids. The WAT also has an endocrine role, through the secretion of adipokines such as leptin, adiponectin and aP2 that regulate
whole-body metabolism, and cytokines such as TNFα, IL1β, and IL6, with local and distal modulatory functions, that may determine the “low grade inflammatory
status” that characterize most obese patients. (B) Types of WAT. Subcutaneous WAT is considered rather innocuous (or even beneficial) and has an important
expansibility potential in healthy individuals. Visceral WAT, on the other hand, is a major player in adiposopathy, as it contributes to the inflammatory state that
characterizes WAT dysfunction. (C) CaSR signaling pathways in WAT. CaSR has both physiological activators, such as Ca2+ and polyamines, and pharmacological
modulators, such as cinacalcet, as well as a variety of allosteric regulators associated with metabolism, such as pH, amino acids, and glutathione. In the adipocyte,
the canonical CaSR-associated pathways are thought to be activated, like ERK, PI3K, NFκB, and Ca2+ elevations and cAMP decreases through Gα proteins. The
adipogenic program is also known to be stimulated by CaSR stimulation.
FIGURE 2 | CaSR contributions to adiposopathy. (A) CaSR activation in visceral WAT preadipocytes leads to increased production of pro-inflammatory cytokines,
proliferation, and differentiation. In adipose cell models, it also enhances pro-inflammatory cytokine production and may decrease lipid accumulation, thereby
contributing to adipose tissue dysfunction. (B) The NFκB-CaSR positive feed-back. CaSR activation leads to increased pro-inflammatory cytokines secretion, which
are known to activate the NFκB pathway. NFκB, in turn, stimulates CaSR gene expression via specialized sequences in the CaSR promoter.
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the proliferation, and proinflammatory cytokine expression in
preadipocytes (Rocha et al., 2015). Moreover, CaSR activation
elevates adipogenesis in visceral preadipose cells (Villarroel et al.,
2013).
Pro-inflammatory Cytokine Expression
Several reports have described how CaSR activation is linked
to inflammation in adipose cells, which is the cardinal feature
of WAT dysfunction. The human adipose cell line LS14, as
well as primary preadipocytes, and adipocytes, not only express
CaSR, but also upregulate its protein levels in response to pro-
inflammatory cytokines, such as IL1β, IL6, and TNFα (Cifuentes
et al., 2010). Furthermore, adipocytes treated with conditioned
medium of WAT explants obtained from obese individuals
also increase their CaSR protein levels. These elevations at
least in part depend on NFκB signaling pathway, as its
inhibitor, SN50, reduces the effect. These findings are consistent
with previous work showing the presence of NFκB response
elements in the CaSR promoter (Canaff and Hendy, 2005).
The CaSR, in turn, increases the secretion of proinflammatory
cytokines in adipose cells (Cifuentes et al., 2012), possibly
resulting in a positive feedback loop. CaSR activation with the
calcimimetic cinacalcet increases the expression of IL1β, IL6,
TNFα, and CCL2 in LS14 preadipocytes and adipocytes as
well as human visceral WAT explants. Again, these changes
were dependent on NFκB signaling in LS14 cells (Cifuentes
et al., 2012), thus highlighting the intimate, tripartite relationship
between CaSR-NFκB-cytokines during inflammation in adipose
cells (Figure 2B).
Higher Visceral Adipogenesis
Studies in both SW872 and LS14 human adipose cell lines
have revealed an adipogenic effect of CaSR (He et al., 2012;
Villarroel et al., 2013). Exposure to CaSR activators increases
the mRNA levels of peroxisome proliferator-activated receptor
γ (PPARγ), a master regulator of the adipogenic genetic
program, thereby upregulating its downstream genes, such as
adipose fatty acid-binding protein (aP2), lipoprotein lipase
(LPL), CCAAT element binding protein α (C/EBPα), glycerol-3-
phosphate dehydrogenase (GPD), and adiponectin. In response
to body fat overload, healthy subcutaneous adipogenesis is
considered a positive measure to increase storage capacity.
However, as aforementioned, not all fat depots are equal, and
increased visceral WAT is associated with inflammation and
obesity-induced cardiovascular and metabolic impairment. In
the case of LS14 cells, they are considered a model of visceral
adipocytes (Hugo et al., 2006; LaPensee et al., 2008). Given their
proinflammatory profile elicited by CaSR activation, this kind of
adipogenesis rather contributes to adiposopathy, instead of its
prevention or relief.
Preadipocyte Proliferation
In both human LS14 and murine 3T3L1 preadipocytes, different
CaSR agonists increase proliferation through the ERK signaling
pathway (Hou et al., 2013; Rocha et al., 2015). This mitogenic
effect of CaSR activation has also been shown in other cell types,
such as rat bonemarrowmesenchymal stem cells (Xu et al., 2012),
and rat osteoblasts (Chattopadhyay et al., 2004). Moreover, the
involvement of the CaSR-ERK signaling axis is consistent with
findings in breast cancer cells (El Hiani et al., 2009). As is the case
for interpreting the adipogenesis observations, being considered
a model of visceral WAT, LS14 proliferation may be linked to the
pathologic effects of obesity, instead of a healthy subcutaneous
WAT remodeling.
Altered Lipid Handling
Numerous epidemiological, clinical, and cell-based studies have
suggested that a diet deficient in calcium is associated with
greater fat accumulation (Villarroel et al., 2014). The proposed
mechanism involves paradoxically greater cytosolic calcium
levels in adipocytes with low calcium diets that trigger changes in
triglyceride metabolism (Zemel and Miller, 2004). Interestingly,
one of the main downstream signaling events triggered by
CaSR activation is elevated cytosolic Ca2+, and rats fed low
calcium diets showed an elevated expression of CaSR in WAT
(He Y. H. et al., 2011). In addition, the low calcium diet was
associated with a decrease in triglyceride breakdown (lipolysis)
in rat WAT, which was dependent on CaSR (He Y. H. et al.,
2011). The low calcium diet also decreased protein levels of
the lipolytic enzymes hormone-sensitive lipase and adipose
triglyceride lipase. Using the SW872 human adipose cell line,
this CaSR-mediated antilipolytic effect was shown to rely on
intracellular Ca2+ augmentation, as well as a decrease in cyclic
AMP (cAMP) and cAMP-dependent protein kinase A (PKA)
signaling (He Y. et al., 2011). Similar results were obtained in
primary human adipocytes, where CaSR activation decreased
lipolysis via Giα protein and phosphoinositide 3 kinase (PI3K)
signaling (Cifuentes and Rojas, 2008). Taken together, the
described findings suggest that even though CaSR stimulates
WAT proliferation and differentiation, it induces alterations in
lipid handling that might contribute to the deleterious effects of
obesity. In this context, it may be of great interest to perform
controlled trials to evaluate possible changes in visceral adiposity
and serum lipid profiles in patients undergoing treatment with
cinacalcet.
Integrative Model
Among the many regulators of the CaSR (reviewed in Cavanaugh
et al., 2012), the polyamines spermine and spermidine are two
orthosteric CaSR agonists with promising roles regarding WAT
metabolism. Obese Zucker rats have four times more spermine
and spermidine in the adipose tissue in comparison with lean
animals, which correlates with increased activity of various
triacylglycerol synthetic enzymes (Jamdar et al., 1996). Aside
from polyamines, other metabolic indicators potentiate CaSR
signaling, such as pH elevations (Doroszewicz et al., 2005),
glutathione (Wang et al., 2006), and amino acids (Lee et al., 2007),
thus supporting the possibility that outside of the parathyroid
gland, CaSR acts more like a metabolic status sensor instead of
a Ca2+ rheostat. Due to CaSR’s unique ability to sense, and thus
potentially integrate a variety of signals through distinct allosteric
sites, it may be considered a sensor of the local metabolic
environment (Breitwieser et al., 2004), which is of great interest
in complex tissues, or pathogenic contexts such as dysfunctional
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WAT and obesity. Additionally, CaSR folding and traffic have
been indicated as key regulators of its activity (Grant et al.,
2011). This is interesting given that in obesity, adipocytes are
subjected to endoplasmic reticulum (ER) stress (Kawasaki et al.,
2012), which specifically compromises protein folding and traffic.
Moreover, CaSR synthesis in the ER includes a folding checkpoint
and retention step (Cavanaugh et al., 2010), which can be
assisted with agonists such as Ca2+ and glutathione (Breitwieser,
2014). Considering that adiposopathy leads to oxidative stress
and altered glutathione metabolism in adipocytes (Kobayashi
et al., 2009), we propose CaSR as a novel potential integrator
of environmental cues, which ultimately contribute to adipose
tissue dysfunction and pathology.
FUTURE STUDIES
Ongoing studies of CaSR in WAT pathophysiology are
contributing to elucidate an important role of the receptor,
mainly in the visceral depot or in models of visceral adipose
cells. Given the fundamental differences between WAT depots,
it is of great relevance that future studies begin to address the
role of the receptor in the subcutaneous fraction. Moreover,
studying the expression and function of the CaSR in obese and
lean individuals, as well as healthy versus unhealthy obese, and
exploring whether there exists a sexual dimorphism in WAT
CaSR expression and function, are relevant pending issues.
For a better insight on the role of CaSR in the pathogenesis
of obesity, studies should also test the effect of CaSR modulation
in different obesity models, such as diet-induced and genetically
modified mice. Given the function of CaSR in multiple tissues,
as well as its preponderance in regulating circulating calcium,
it should be considered to modulate its function locally at the
WAT. Additionally, its role during the onset and progression of
fat accumulation should be tested.Moreover, theWATof patients
with activating or downregulating mutations in the CaSR should
be analyzed, in order to detect disturbances in their metabolic or
inflammatory state.
In recent years, not only WAT, but also brown adipose
tissue (BAT) has received increasing attention. BAT is a type of
adipose tissue characterized for being thermogenic and rather
metabolically active instead of storage-oriented (Pellegrinelli
et al., 2016). Different reports have shown its presence and
activity in healthy adult humans, where up to recent years it
was thought to be irrelevant (Cypess et al., 2009; Saito et al.,
2009; van Marken Lichtenbelt et al., 2009; Virtanen et al.,
2009). BAT is a promising target in the treatment of metabolic
diseases, as it inversely correlates with body weight and fasting
circulating glucose (Lee et al., 2010). Cold exposure has been
shown to stimulate BAT presence in humans (Hanssen et al.,
2016) probably through transdifferentiation of WAT (Frontini
et al., 2013). White-to-brown transdifferentiation, commonly
termed “browning” or “beigeing,” has been shown to occur
only in subcutaneous (Fisher et al., 2012) but not in visceral
WAT, further underscoring the differences between both types
of adipose tissue and the need to explore the role of CaSR in
the subcutaneous depot. Studies are required to assess the role of
CaSR in BAT metabolic and regulatory functions, and also to test
whether CaSR pro-inflammatory effect negatively affects WAT
browning.
CONCLUSION
Obesity is a complex and multifactorial disease, and even
though it is known that energy imbalance is at the core of
the problem, it has been extremely difficult to decrease or
control the worldwide obesity epidemic. Current efforts aim to
reduce obesity-related diseases by better understanding WAT
physiology and maintaining its adequate function. The CaSR in
WAT is emerging as an important molecule whose activation
has been shown to increase the inflammatory state. Moreover,
CaSR activation also promotes the proliferation of WAT under
inflammatory conditions, which is known to yield less functional
fat depots that rather contribute to pathogenesis than to lipid
storage. In this sense, inhibition of CaSR activity in the WAT
of obese patients may represent a novel therapeutic approach
in this obesity epidemic era. The effects here described are in
accordance with recent findings indicating that CaSR activation
participates in many inflammatory processes, such as recognition
of necrotic cells (Rossol et al., 2012) and pathologies like asthma
(Yarova et al., 2015), myocardial infarction (Liu et al., 2015),
and sepsis (Wu et al., 2015). On the other hand, CaSR-induced
inflammation in the gastrointestinal tract has been proposed
to be a conditioning agent for the appropriate function of the
intestinal epithelial barrier (Owen et al., 2016). Thus, further
research should evaluate the potential impact of CaSR activation
as a pharmacological target in the pathogenesis of WAT
dysfunction.
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